Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 5/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 5/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 5/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 11/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15785297 | 0.86 | TNK2 (0.43) | RIPK2ACVR1NOD2TNK2SRC | |
| SCHEMBL13553683 | 0.82 | SRC (0.40) | RIPK2ACVR1NOD2TNK2SRC | |
| SCHEMBL15041858 | 0.78 | TNK2 (0.41) | RIPK2ACVR1NOD2TNK2SRC | |
| SCHEMBL15785359 | 0.76 | RIPK2 (0.39) | RIPK2ACVR1NOD2TNK2SRC | |
| SCHEMBL15036050 | 0.75 | TNK2 (0.48) | TNK2SRC | |
| SCHEMBL15035671 | 0.74 | TNK2 (0.49) | TNK2SRCPAK4PKN1 | |
| SCHEMBL14682001 | 0.74 | RIPK2 (0.47) | RIPK2ACVR1NOD2TNK2SRC | |
| SCHEMBL15036122 | 0.74 | RIPK2 (0.47) | RIPK2ACVR1NOD2TNK2SRC | |
| SCHEMBL15035101 | 0.73 | RIPK2 (0.46) | RIPK2ACVR1NOD2TNK2SRC | |
| SCHEMBL15035028 | 0.73 | TNK2 (0.48) | TNK2SRCPAK4PKN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK5 | RIPK2 1295/4885ACVR1 4838/4885NOD2 4077/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | RIPK2 971/4885ACVR1 4752/4885NOD2 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.